The FDA labels for Zepbound and Wegovy both list acute cholecystitis and gallstones as possible risks
Additionally, a double-blind, parallel-group, placebocontrolled trial (considered the gold standard in clinical research) was conducted on 50- to 80-year-old Japanese individuals diagnosed with mild cognitive impairment to examine the efficacy of oral administration (3 gms/day mycelial powder) of Lions Mane ( Hericium erinaceus ) [13] The Lions Mane group showed significantly increased scores on the cognitive function scale compared with the placebo group at weeks 8, 12, and 16 of the trial
Currently, there is no antioxidant indicated for any CV disease [except for dexrazoxane in anthracycline toxicity (252) which can produce severe adverse effects and its use is limited(ref)] due to few and small clinical trials which were not necessarily following the results from preclinical studies
Core Peptides has taken a meaningful share of the research market by balancing quality with affordability on standard single compounds, and it is a common choice for university laboratories managing costs
The earliest expected NDA filing with the FDA is Q4 2026, which would put a realistic FDA decision in 2027 or later
